form8_k91609.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) September 14,
2009
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
777
Old Saw Mill River Road, Tarrytown, New York
|
|
10591
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's telephone number,
including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
September 14, 2009, the Board of Directors of Progenics Pharmaceuticals, Inc.
(Nasdaq: PGNX) elected Mark R. Baker President of the Company and a member of
its Board of Directors, increasing the number of directors of the Company to
nine. Mr. Baker, formerly the Company’s Executive Vice President –
Corporate, General Counsel and Secretary, will retain the latter titles and
continue to report to Paul J. Maddon, M.D., Ph.D., the Company’s Founder, Chief
Executive Officer and Chief Science Officer. Mr. Baker will serve as
a director, subject to his earlier resignation or removal, until the Company’s
2010 annual meeting of stockholders and the election and qualification of his
successor. He will not receive any additional compensation for
service as a director. Additional information concerning Mr. Baker
contained in the Company’s Proxy Statement for its Annual Meeting of
Stockholders held on June 8, 2009 is incorporated herein by reference
thereto.
The
Company’s press release announcing Mr. Baker’s election as President and a
director is attached as Exhibit 99.1, and the information contained therein is
incorporated by reference into this Item 5.02 of this Current Report on Form
8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. Description
|
99.1
|
Press
Release dated September 16, 2009.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/ ROBERT A.
MCKINNEY
Robert A. McKinney
Chief Financial Officer, Senior
Vice President,
Finance & Operations and
Treasurer
Date: September
16, 2009